Evidence map›Paper›PMID 24416081›Full record

ArticleAnalytical methods : advancing methods and applications2013

LC-MS/MS quantification of salvinorin A from biological fluids.

Michael J Caspers, Todd D Williams, Kimberly M Lovell, Anthony Lozama, Eduardo R Butelman, Mary Jeanne Kreek, Matthew Johnson, Roland Griffiths, Katherine Maclean, Thomas E Prisinzano

Abstract read
In one paragraph

Article in Analytical methods : advancing methods and applications, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Salvinorin A andInternational journal of molecular sciences · 2025
    Review
  2. Pharmacokinetics and Pharmacodynamics of Salvinorin A andPharmaceuticals (Basel, Switzerland) · 2021
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michael J CaspersDepartment of Medicinal Chemistry, The University of Kansas, Lawrence, Kansas 66045, United States.
Todd D WilliamsDepartment of Medicinal Chemistry, The University of Kansas, Lawrence, Kansas 66045, United States.
Kimberly M LovellDepartment of Medicinal Chemistry, The University of Kansas, Lawrence, Kansas 66045, United States.
Anthony LozamaDivision of Medicinal & Natural Products Chemistry, University of Iowa, Iowa City, Iowa 52242, United States.
Eduardo R ButelmanThe Rockefeller University, New York, New York 10065, United States.
Mary Jeanne KreekThe Rockefeller University, New York, New York 10065, United States.
Matthew JohnsonDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, United States.
Roland GriffithsDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, United States.
Katherine MacleanDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, United States.
Thomas E PrisinzanoDepartment of Medicinal Chemistry, The University of Kansas, Lawrence, Kansas 66045, United States.

Funding

ULTRASTUCTURE, RECEPTORS, AND GENE EXPRESSIONP60DA005130 · NIDA · ROCKEFELLER UNIVERSITY · PI KREEK, MARY J · 2002 to 2012
$30.6M
Human Clinical Pharmacology of Emerging Drugs of Abuse (Club Drugs)R01DA003889 · NIDA · JOHNS HOPKINS UNIVERSITY · PI GRIFFITHS, ROLAND R · 1985 to 2017
$7.6M
Investigation of Neoclerodanes as Novel Opioid LigandsR01DA018151 · NIDA · UNIVERSITY OF KENTUCKY · PI PRISINZANO, THOMAS EDWARD · 2005 to 2020
$5.7M
UNIQUE RNA STRUCTURE OF CAUSATIVE AGENT FOR DELTA HEPATITISP50DA005130 · NIDA · ROCKEFELLER UNIVERSITY · PI YU, JUN · 1987 to 2001
$5.0M
kappa-agonist effects of the hallucinogen Salvinorin AR01DA017369 · NIDA · ROCKEFELLER UNIVERSITY · PI BUTELMAN, EDUARDO R · 2005 to 2008
$814k
NIDA NIH HHS P50 DA005130NIDA NIH HHS P60 DA005130NIDA NIH HHS R01 DA003889NIDA NIH HHS R01 DA017369NIDA NIH HHS R01 DA018151
6 · The paper itself

Abstract

A facile method for quantifying the concentration of the powerful and widely available hallucinogen salvinorin A (a selective kappa opioid agonist) from non-human primate cerebrospinal fluid (CSF) and human plasma has been developed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in positive electrospray ionization (ESI) mode. With CSF solid phase extraction can be avoided completely by simply diluting each sample to 10 % (v/v) acetonitrile, 1 % (v/v) formic acid and injecting under high aqueous conditions for analyte focusing. Extensive plasma sample preparation was investigated including protein precipitation, SPE column selection, and plasma particulate removal. Human plasma samples were centrifuged at 21,000 × gravity for 4 minutes to obtain clear particulate-free plasma, from which 300 μl was spiked with internal standard and loaded onto a C

Identifiers

PMID24416081
PMCPMC3885280

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.